Duration and dose of chemotherapy and dental development

Jodłowska, Anna; Postek−Stefańska, Lidia

doi:10.17219/dmp/138914

Cited by 7 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study by the author, no significant differences in therapy duration were found between the affected and non-affected survivors within almost all groups of dental abnormalities for each drug. An exception was established for microdontia in the DXR group ( p = 0.04), with the therapy longer in affected survivors and a reduction in crown size in patients treated with CP ( p = 0.03), with a paradoxically longer treatment duration in non-affected participants [ 27 ]. Proc et al also demonstrated that the distribution of microdontic teeth depended on the age during anticancer treatment [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…In some cases, treatment duration was even longer in the non-affected group than in the group with analyzed abnormality. Some strong significant correlations were also found between analyzed values; however, no reliable conclusions were established based on these observations [ 27 ]. In conclusion, it has not been determined yet whether the intensification of therapy is the reason for more common dental changes.…”

Section: Introductionmentioning

confidence: 99%

“…No authors to date have addressed the problem. Only cumulative drug doses were studied [ 7 , 27 , 28 ]. On the other hand, owing to the fact that developing dental tissues are highly susceptible to toxic impairment, similarly to cancer cells, even a small dose of the drug could cause irreversible changes in odontogenesis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Systemic Anticancer Therapy Details and Dental Adverse Effects in Children

Jodłowska

Postek−Stefańska

2022

IJERPH

Self Cite

View full text Add to dashboard Cite

An idea of therapy intensification in order to make anticancer treatment more effective is still being investigated. The study aimed to estimate the impact of the chemotherapy dose levels and treatment duration on the risk for dental development disturbance. The clinical examination and OPG analysis were carried out in 37 cancer survivors and germ agenesis, microdontia, size reduction, taurodontism, root and enamel abnormalities were identified. An analysis of anticancer treatment was carried out separately for vincristine (VCR), doxorubicin (DXR), cyclophosphamide (CP), etoposide (VP-16), carboplatin (CBDCA) and actinomycin D (ACTD) recipients in terms of treatment duration and drug doses administered. Individuals aged between three years and ten months, and seven years and four months, at diagnosis presented with no severe dental abnormalities, regardless of treatment duration and increasing cytotoxic drug doses. The largest number of abnormalities per one person was noted in the survivors treated with the highest single doses of VCR, DXR, CP and ACTD. No similar observation was made in the cases of cumulative and weekly doses analyzed. Moreover, there were no significant differences between the mean number of abnormalities across all the drug groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic Anticancer Therapy Details and Dental Adverse Effects in Children

Jodłowska

Postek−Stefańska

2022

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has already been proven that young cancer survivors presenting with the most severe dental changes had been receiving chemotherapy before they were 3-5 years old. Furthermore, they exhibited no dental abnormalities if they had been treated at the age between 43 and 61 months [5,6,10,[15][16][17][18][19][20][21][22]. Some scientific works investigated the influence of individual therapeutic agents on the frequency of dental anomalies appearance [5,15,16,23].…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, they exhibited no dental abnormalities if they had been treated at the age between 43 and 61 months [5,6,10,[15][16][17][18][19][20][21][22]. Some scientific works investigated the influence of individual therapeutic agents on the frequency of dental anomalies appearance [5,15,16,23]. However, the multidrug character of anticancer treatment seems to be a major limitation in terms of reliable assessment of the above-mentioned dependencies.…”

Section: Introductionmentioning

confidence: 99%

Tooth Abnormalities and Their Age-Dependent Occurrence in Leukemia Survivors

Jodłowska,

Postek-Stefańska

2023

Cancers

Self Cite

View full text Add to dashboard Cite

The multidrug nature of anticancer treatment and different treatment protocols used in the studies are likely to be a major limitation in establishing real risk factors determining the occurrence of dental abnormalities. The authors aimed to establish a relationship between the duration and the dose of chemotherapy and the number of tooth adverse effects in the group receiving the same treatment. Of the 40 anticancer therapy recipients who attended the outpatient dental clinic, 7 leukemia survivors receiving the treatment according to the ALL IC-BFM 2002 protocol were selected. The study group consisted of four females and three males aged 92 to 207 months at the time of dental examination and 29 to 91 months at leukemia diagnosis. As a result of the clinical and radiological examination, dental abnormalities such as agenesis, tooth size reduction, root abnormalities, and taurodontia were identified, and the medical records of all survivors were reviewed in terms of drugs administered, their doses, and treatment schedules. No correlation was observed between the treatment duration of an intensive therapy, the entire therapy, and the number of tooth abnormalities. No relationship was also found between the number of dental abnormalities and the cumulative dose of vincristine, L-asparaginase, methotrexate, cyclophosphamide, cytarabine, and 6-mercaptopurine. The age at the onset of antineoplastic therapy is likely to be the strongest risk factor for toxic injury during tooth development.

show abstract